<DOC>
	<DOC>NCT02768974</DOC>
	<brief_summary>This is a proof of concept, randomized, open label, 2-arm study of OPRX-106 in subjects with active mild to moderate ulcerative colitis. Eligible subjects will be enrolled and randomized to receive 2 mg or 8 mg of OPRX-106 administered orally, once daily for 8 weeks.</brief_summary>
	<brief_title>Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Main 1. Have had a diagnosis of ulcerative colitis for a minimum of 3 months 2. Have active mild to moderate ulcerative colitis, as defined by a full Mayo score at screening 3. Have adequate cardiac, renal and hepatic functions as determined by the investigator and demonstrated by screening clinical and laboratory evaluations, and physical examination results 4. High level of calprotectin (&gt;100 mg/kg of stool) Main 1. Have a history of colonic or rectal surgery other than hemorrhoidal surgery or appendectomy 2. .Positive for active/ latent mycobacterium tuberculosis (TB) infection 3. .Have a history of infection requiring administration of any IV antibiotic, antiviral or antifungal medication or any oral antiinfective agent 4. Severe ulcerative colitis 5. Ulcerative proctitis, defined as disease limited to less than 15 cm from the anal verge 6. Use &gt;4.8 g 5ASA or equivalent 7. Use of corticosteroid or 5ASA enemas, foams, or suppositories 8. Use of antiinflammatory medications or natural remedies 9. Use oral or parenteral antibiotics 10. Use of chronic nonsteroidal antiinflammatory (NSAID) therapy 11. Use of immune suppressive agents including antiTNF agents, Azathioprine, 6MP, Methotrexate 12. Use of steroids 13. Have a diagnosis of: Crohn's disease; Indeterminate colitis; Microscopic colitis; Ischemic or infectious colitis; Clostridium difficile colitis, Parasitic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>